Subject(s)
Neoplasm Recurrence, Local/radiotherapy , Neoplasms, Second Primary/radiotherapy , Otorhinolaryngologic Neoplasms/radiotherapy , Radiotherapy, Conformal/methods , Radiotherapy, Intensity-Modulated/methods , Chemoradiotherapy , Combined Modality Therapy , Humans , Neoplasm Recurrence, Local/surgery , Neoplasms, Second Primary/surgery , Otorhinolaryngologic Neoplasms/surgery , Radiotherapy, Adjuvant , Retrospective StudiesABSTRACT
While most of the studies examining radiosurgery for trigeminal neuralgia have used a Gamma Knife, a linear accelerator can also be utilized for treatment. We report on 20 patients with trigeminal neuralgia who received 23 treatments with a linear accelerator that delivered a maximum dose of 82.3-100 Gy. The median patient follow-up was 56.5 months, 70% of patients had received previous surgical treatment and 20% had secondary (nonessential) trigeminal neuralgia. Eight (35%) radiosurgery treatments resulted in complete pain relief; 5 (63%) patients with initial pain relief had pain recurrence at a mean time of 21.5 months. Ten (43%) patients reported a 50% or more decrease in pain severity but have not achieved a pain-free state. A total of 18 (78%) treatments resulted in no pain or a 50% or greater improvement in pain. Five treatments (22%) resulted in less than 50% improvement in pain. We conclude that linear accelerator stereotactic radiosurgery is a viable treatment option for trigeminal neuralgia patients, especially for patients who have not had a previous invasive treatment.
Subject(s)
Radiosurgery , Trigeminal Neuralgia/surgery , Adult , Aged , Aged, 80 and over , Analysis of Variance , Follow-Up Studies , Humans , Middle Aged , Radiosurgery/methods , Radiosurgery/statistics & numerical data , Time Factors , Trigeminal Neuralgia/physiopathologyABSTRACT
PURPOSE: To examine radiation dose response for low-grade glioma (LGG) based on our institutional experience and to review the literature on this topic. METHODS AND MATERIALS: Sixty-seven patients with supratentorial low-grade nonpilocytic astrocytomas (n=36) or oligodendrogliomas (n=31) were treated with postoperative radiation therapy (RT). Twenty-seven patients (group A) received 5520 cGy; 24 patients (group B) received 5940 cGy; and 16 patients (group C) received 6375 cGy. The corresponding median follow-up was 60, 35 and 91 months, respectively. RESULTS: The disease-specific survival (DSS) at 5 and 10 years were 90.2% and 56.2%, 67.6% and 47.3%, and 62.5% and 50% for groups A, B and C, respectively (P=0.40). Only a greater extent of surgical resection and absence of contrast enhancement predicted DSS on multivariate analyses. Patients receiving higher doses of RT had higher complication rates. CONCLUSION: Our data confirmed the lack of radiation dose response for supratentorial LGG as demonstrated in the previous randomized trials. The radiation dose should not exceed 5520 cGy because dose escalation did not result in an improvement of DSS and it also increased the complication rates. Future research should focus on the eradication of radioresistant clones either by the improvement of surgical resection or the use of cytotoxic agents that can target on the radioresistant tumor cells.